Provention Bio Reports Second Quarter 2020 Financial Results and Provides Business Update

- Completed commercial-scale drug substance PPQ campaign ahead of schedule, enabling the expected on-time completion of the rolling Biologics License Application (BLA) submission for teplizumab in Q4 2020 - - Expect to submit clinical module of rolling BLA for teplizumab in Q3 2020 - - Extended follow-up results from the pivotal "At-Risk" TN-10 Study presented at ADA demonstrated that teplizumab significantly delays the onset of insulin-dependent T1D by a median of approximately three years compared to placebo -

Thank you for visiting Tailwinds Research. We are pleased to offer free research on select small and micro cap companies. It is free to join and we hope you’ll take the time to do so.

To create an account please click on this link.

If you already have an account, please log in here.

LEAVE A REPLY

Please enter your comment!
Please enter your name here